Type:
Educational Exhibit
Keywords:
Molecular imaging, Nuclear medicine conventional, Education, Cancer
Authors:
J. Gajera, H. Ireland, J. Drummond, E. Hsiao, G. Schembri, M. Back; Sydney, NSW/AU
DOI:
10.26044/ranzcr2021/R-0072
Background
Positron emission tomography (PET) is gaining widespread use in the evaluation of brain tumours. PET-tracers currently used for imaging glial tumours in Australia are largely radiolabelled amino acid tracers. These tracers are preferentially taken up by tumour cells due to an overexpression of amino acid transporters on their cell surface, while their uptake in background normal brain tissue is relatively low. Numerous studies related to [18F]FluoroEthyl-L-Tyrosine (18F-FET-PET) in gliomas have been published by our group and in the literature1, 2. Our clinical experience and findings from selected recently published articles on the role of 18F-FET-PET in neuro-oncology are described.